

Zaka VC Invests in DeepSeq.AI to Transform AI-Based Protein Drug Discovery

FOSTER CITY, CA, UNITED STATES, January 7, 2026 /EINPresswire.com/ -- DeepSeq.AI, Inc. (DeepSeq), a privately held biotech company transforming AI-based protein drug discovery using hyperscaled data, is proud to announce an investment from ZAKA

VC, a prominent Czech-based VC that has become one of the most active early-stage investors in Europe. DeepSeq's proprietary LLM-based technology can generate and analyze huge experimental datasets for protein (biologics) drug discovery, including large-scale protein-protein interaction (PPI) data, allowing its AI algorithms to discover better drug candidates.



DeepSeq.AI

Transforming AI-Based Protein Drug Discovery Using HyperScaled Data



The team brings a strong balance of scientific and commercial expertise, has built a unique data foundation with a compelling moat, and has already demonstrated promising early traction."

Jan Kasper, Co-Founder and Managing Partner at Zaka VC

ZAKA VC's investment, together with investment funding from Illumina Ventures and leading biotech-related family offices, will be used to scale DeepSeq's data sets and development teams to meet the demand for future collaborations and partnerships related to protein drug discovery.

"As an active investor in the biotech community, ZAKA VC's participation in our funding round, together with other prominent investors like Illumina Ventures, shows the tremendous promise and value of DeepSeq's approach. Our large-scale PPI and other data sets, validated through

a DARPA-funded initiative, will allow our AI algorithms to efficiently discover better protein drug candidates," said DeepSeq co-founder and CEO Andrew Chang, Ph.D.

"We are pleased to welcome DeepSeq to the Zaka VC portfolio," said Jan Kasper, Co-Founder and Managing Partner at Zaka VC. "The team brings a strong balance of scientific and commercial expertise, has built a unique data foundation with a compelling moat, and has already demonstrated promising early traction. Their clear, disciplined thinking around building a scalable protein drug discovery platform gives us strong conviction in their long-term potential."

About DeepSeq

DeepSeq is a leading protein drug discovery startup, seeking to transform AI-based protein drug discovery using hyperscaled data. Backed by leading accelerators Merck Digital Sciences Studio (DSS), Stanford StartX and Berkeley SkyDeck, DeepSeq also has received grant awards from DARPA and NSF. DeepSeq's commercially available platform is already used by many big pharma customers and the company furthermore has been recognized with the 2025 Astellas Future Innovators award and the 2024 MBC Biolabs/ONO "Golden Ticket" award. For more information, visit www.deepseq.ai.

About Zaka VC

ZAKA VC is an early-stage VC fund bridging Europe and North America. Originally formed as a family office in 2019, ZAKA VC has rapidly become one of the most active investors in Europe. Since 2024, Zaka VC operates as a VC fund. Due to increasing activity and networks in the United States and Canada, ZAKA VC established an office in San Francisco, California to oversee our activities in North America. The firm focuses on investment in the Biotech, Healthcare, and Industrial Tech verticals. For more information, visit www.zaka.vc.

PR Department
DeepSeq.AI, Inc.
info@deepseq.ai

This press release can be viewed online at: <https://www.einpresswire.com/article/879998435>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.